Wermer, Marieke J H
Mayo Clinic
University Medical Center Groningen
Citations 2
Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society
Lennep, Jeanine E. Roeters van , Tokgözoğlu, Lâle , Badimón, Lina , Dumanski, Sandra M. , Gulati, Martha , Hess, Connie N. , Holven, Kirsten B. , Kavousi, Maryam , Kayıkçıoğlu, Meral , Lutgens, Esther , Stock, Jane K., Tybjærg‐Hansen, Anne, Benn, Marianne , Roeters van Lennep, Jeanine E , Michos, Erin D , Prescott, Eva , Wermer, Marieke J H , Benn, Marianne , Lutgens, Esther , Kavousi, Maryam , Michos, Erin D.
European Heart Journal | July 26, 2023 | Volume: 44 | Issue: 39 | Pages: 4157-4173
Abstract Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 years, ASCVD mortality is now increasing, with the fastest relative increase in middle-aged women. Missed or delayed diagnosis and undertreatment do not fully explain this burden of disease. Sex-specific factors, such as hypertensive disorders of pregnancy, premature menopause (especially primary ovarian insufficiency), and polycystic ovary syndrome are also relevant, with good evidence that these are associated with greater cardiovascular risk. This position statement from the European Atherosclerosis Society focuses on these factors, as well as sex-specific effects on lipids, including lipoprotein(a), over the life course in women which impact ASCVD risk. Women are also disproportionately impacted (in relative terms) by diabetes, chronic kidney disease, and auto-immune inflammatory disease. All these effects are compounded by sociocultural components related to gender. This panel stresses the need to identify and treat modifiable cardiovascular risk factors earlier in women, especially for those at risk due to sex-specific conditions, to reduce the unacceptably high burden of ASCVD in women.
Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy
Shirzadi, Zahra , Yau, Wai‐Ying Wendy , Schultz, Stephanie A. , Scott, Matthew R. , Goubran, Maged , Mojiri‐Forooshani, Parisa, Joseph‐Mathurin, Nelly , Kantarci, Kejal , Preboske, Greg M., Taddei, Kevin , Sohrabi, Hamid R. , Johnson, Keith A. , Bateman, Randall J. , Martins, Ralph N. , Greenberg, Steven M. , Chhatwal, Jasmeer P. , Investigators, DIAN, Vöglein, Jonathan , Yau, Wai-Ying W , Joseph-Mathurin, Nelly , Kantarci, Kejal , Preboske, Greg, Bateman, Randall J , Vöglein, Jonathan , Schultz, Aaron P. , Wermer, Marieke J H , Jack, Clifford R. , Benzinger, Tammie L.S. , Sperling, Reisa Anne , Investigators, DIAN
Annals of Neurology | June 7, 2022 | Volume: 92 | Issue: 3 | Pages: 358-363
Autosomal‐dominant, Dutch‐type cerebral amyloid angiopathy (D‐CAA) offers a unique opportunity to develop biomarkers for pre‐symptomatic cerebral amyloid angiopathy (CAA). We hypothesized that neuroimaging measures of white matter injury would be present and progressive in D‐CAA prior to hemorrhagic lesions or symptomatic hemorrhage. In a longitudinal cohort of D‐CAA carriers and non‐carriers, we observed divergence of white matter injury measures between D‐CAA carriers and non‐carriers prior to the appearance of cerebral microbleeds and >14 years before the average age of first symptomatic hemorrhage. These results indicate that white matter disruption measures may be valuable cross‐sectional and longitudinal biomarkers of D‐CAA progression. ANN NEUROL 2022;92:358–363